Drug Profile
Research programme: caspase inhibitors - Pfizer
Latest Information Update: 27 Nov 2007
Price :
$50
*
At a glance
- Originator Idun Pharmaceuticals
- Class
- Mechanism of Action Caspase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Liver disorders; Myocardial infarction; Sepsis; Vascular disorders
Most Recent Events
- 19 Apr 2005 Idun Pharmaceuticals has been acquired by Pfizer
- 28 Oct 2003 This programme is still in active development
- 15 Feb 2001 Preclinical development for Sepsis in USA (Unknown route)